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CLINICAL INVESTIGATION
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Hypertension in autosomal dominant polycystic kidney disease. Auto-
somal dominant polycystic kidney disease (ADPKD) has been shown to
be associated with a greater than 50 percent incidence of hypertension
prior to deterioration in renal function as assessed by glomerular
filtration rate. The present study provides evidence for increased
cardiac pre-load, as assessed by plasma atrial natriuretic factor (ANF)
and cardiac index, in hypertensive as compared to normotensive
ADPKD. The hypertensive ADPKD patients exhibited an increased
renal vascular resistance as compared to the normotensive patients in
spite of comparable glomerular filtration rates. It is hypothesized that
the renal involvement of hypertensive ADPKD patients causes an
impaired renal response to the observed increase in cardiac index, and
also may release a venoconstrictor (such as angiotensin) which contrib-
utes to the enhanced cardiac pre-load and thus the hypertension.
Hypertension is a common complication of autosomal dom-
inant polycystic kidney disease (ADPKD), occurring in up-
wards of 50 to 75 percent of the population [1—10]. This high
prevalence rate initially was attributed to the development of
end-stage renal disease. However, as early as 1931 Schacht
noted that the 75 percent incidence of hypertension in ADPKD
subjects greatly exceeded the 26 percent incidence noted in age
and sex matched controls with end-stage renal disease second-
ary to pyelonephritis [2]. Subsequently, Hansson et at in 1974
found a 75 percent incidence of hypertension in patients with
ADPKD and normal serum creatinine concentrations [9].
Gabow, Ikie and Holmes in 1984 also noted a 62 percent
incidence of hypertension in 192 ADPKD patients without
azotemia [10]. Thus it appears that hypertension is an early
event in the natural history of ADPKD.
The pathogenesis of the hypertension in ADPKD, however,
remains to be elucidated. The structural alterations of the
kidney by the cysts with stretching and alteration of renal
vessels and tubular disruption makes it reasonable to hypothe-
size that either the renin-angiotensin and/or tubular handling of
sodium could be important factors in the pathogenesis of the
hypertension. However, previous studies have been unable to
implicate definitively either the renin-angiotensin system or an
increased plasma volume as a mechanism of the hypertension.
Anderson et at in 1975 examined the blood pressure response to
angiotensin II antagonism with saralasin in hypertensive
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ADPKD patients and were unable to find any evidence for a
role of the renin-angiotensin system in the pathogenesis of
hypertension in ADPKD [11].
The cardiac index was reported to be elevated in hyperten-
sive ADPKD patients by Valvo et a! [12]. However, Brod et al
found normal cardiac indices in eight hypertensive ADPKD
subjects [13]. Nash found variable increases in plasma volume
in seven patients with ADPKD, hypertension, and creatinine
clearances greater than 70 mllmin [141. Although Valvo et at
found an increase in plasma volume in hypertensive ADPKD
patients as compared to normotensive ADPKD subjects, some
of the hypertensive patients had advanced renal failure [12].
Since no clear mechanism emerged for these previous inves-
tigator's studies, we studied hypertensive and normotensive
ADPKD subjects who were not azotemic in order to further
examine the role of the renin-angiotensin-aldosterone system
and the determinants of volume and sodium handling in the
pathogenesis of hypertension. In addition, given the role of the
sympathetic nervous system in some forms of hypertension
[15—18], the potential role of sympathetic activity in the hyper-
tension of ADPKD was also examined.
Methods
Study population
All patients entered into the study had ADPKD documented
by ultrasonographic studies, as defined by the presence of at
least five renal cysts occurring bilaterally. Eligibility criteria
included a measured creatinine clearance  70 mI/mm, age
range 20 to 50 years, a negative serum pregnancy test in
females, and no history of heart disease, cerebrovascular dis-
ease, or other major medical illnesses. Hypertension was de-
fined as persistent diastolic blood pressures greater than or
equal to 100 mm Hg, and normotension was defined as diastolic
blood pressures less than or equal to 85 mm Hg, as measured on
at least three occasions. Antihypertensive medications were
withdrawn one week prior to enrollment into the study.
Study protocol
Patients were hospitalized on the Clinical Research Center
(CRC) at the University of Colorado Health Sciences Center.
Fifteen subjects were initially placed on a 20 mEq sodium/80
mEq potassium diet per day for five days, followed by a 300
mEq sodium/80 mEq potassium diet per day for five days. The
first subject studied in the hypertensive group was initially
placed on 150 mEq sodium/80 mEq potassium diet for five days
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and then 20 mEq sodium/80 mEq potassium diet for an addi-
tional five days. Daily blood pressure measurements and
weights were recorded, and daily 24-hour urines were collected
for sodium and creatinine.
Mean arterial pressure (MAP) was determined by diastolic
pressure plus one-third the pulse pressure. On the day of
admission blood was obtained from an indwelling forearm
venous catheter for sodium, potassium, chloride, total content
C02, blood urea nitrogen (BUN), creatinine, calcium, phospho-
rus, albumin, hemoglobin, hematocrit, osmolality (Osm), plas-
ma renin activity (PRA), aldosterone, norepinephrine (NE), and
atrial natriuretic factor (ANF).
A clonidine suppression test was also performed the morning
of admission [19]. Following a light breakfast without caffeine
or cigarettes, supine blood pressure and pulse were measured
on three separate occasions five minutes apart. Three hundred
micrograms of clonidine were then administered, and supine
blood pressure and heart rate were obtained every thirty
minutes for six measurements. Exactly three hours after taking
the clonidine, a second sample for NE was obtained via the
indwelling catheter. On the low sodium diet inulin and para-
aminophippurate (PAH) were administered intravenously and
three 30-minute urine and blood samples were obtained for
calculation of creatinine, inulin, and PAH clearances.
Twenty-four hour urine collections for urinary prostaglandin
(POE2) were obtained on the third day of both the low and high
sodium diets. On days four and five of both the low sodium and
high sodium diets the following studies were carried out:
I. Blood samples. Two hour supine and upright blood sam-
ples were obtained from an indwelling forearm venous catheter
for sodium, potassium, Osm, PRA, aldosterone, NE, and ANF.
2. Cardiac index. Cardiac output (CO) was measured by the
CO2 rebreathing method [20] at rest and after five minutes of
walking on a treadmill at ten percent grade and 1.7 miles per
hour. At this work load, oxygen consumption and carbon
dioxide production were stable after two and one-half minutes.
Blood pressure was measured with a sphygmomanometer.
Diastolic pressure was taken at the fifth phase Korotkoff sound.
In our laboratory there is good correlation between measure-
ments of cardiac output by the Fick and CO2 rebreathing
methods (r = 0.82; N = 8). The cardiac index (CI) was
calculated by dividing the cardiac output by the body surface
area, and total peripheral resistance (TPR) was calculated
utilizing the following formula and expressed as dyne
sec min5:
MAP x 80TPR =
CO
Immediately following measurement of CO with exercise, blood
was drawn from an indwelling venous catheter for Na, K, Osm,
PRA, aldosterone, NE, and ANF while the patients continued
to exercise.
3. Blood and plasma volumes. Total blood volume and
plasma volume were measured by chromium 51 tagged red
blood cells administered on day four of the low sodium diet; a
subsequent blood sample was obtained on day four of the high
sodium diet, and the blood volumes were recalculated based on
the known radioactive decay of chromium and the change in
hematocrit.
4. Mean arterial pressure and phentolamine. In addition to
the clonidine test, to functionally assess the contribution of the
sympathetic nervous system, phentolamine was administered
intravenously after obtaining three baseline blood pressures and
heart rates by Dinamap (Critikon, Tampa, Florida, USA).
Blood pressures and heart rates were subsequently measured
by Dinamap at three minute intervals throughout the study. An
initial dose of 0.2 mg/mm of phentolamine for ten minutes was
given, then the dose was increased in 0.2 mg/mm increments at
ten minute intervals until a maximum dose of 1.0 mg/mm
(cumulative dose 30 mg) was given, a ten percent fall in mean
arterial pressure occurred, or an increase in heart rate of 15
beats per minute was observed.
5. Captopril study. On the subsequent day on both the low
and high sodium diets, the angiotensin converting enzyme
inhibitor, captopril, was given orally after obtaining three
baseline blood pressures by Dinamap. An initial dose of 25 mg
was administered, followed by blood pressure measurements
every ten minutes. One hour after 25 mg of captopril was given,
a blood sample for PRA was obtained.
The study was terminated after a ten percent fall in MAP had
occurred. Two hours after 25 mg of captopril, if no change in
MAP occurred, 50 mg of captopril was administered. A 100mg
final dose of captopril was administered two hours later if MAP
had not changed.
Serum sodium, potassium, chloride, CO2, BUN, ereatinine,
calcium, phosphorus, albumin, Osm, and complete blood
count, as well as urine sodium and creatinine were measured by
the CRC Core laboratory. Plasma NE was assayed radioenzy-
matically by the CRC laboratory [21], plasma renin activity
[221, aldosterone [231, and ANF [24] were measured by radio-
immunoassay. Urinary POE2 was measured by Walker's
method [25]. Secretory rates were not performed even though
we acknowledge additional information may have been derived
from such results.
All data are expressed as mean standard error of the mean
(5EM). Comparisons between the hypertensive group and the
normotensive group were done by Fisher's Exact test for
categorical data and approximate Wilcoxon's rank sum test
(t-test on the ranks) for continuous data. Before and after
comparisons within groups were performed using Wilcoxon's
signed-rank test. Statistical significance was defined as P C
0.05.
Results
Baseline results
Nine hypertensive subjects and seven normotensive subjects
with ADPKD participated in the study. The initial subject in the
HBP group was included in all analyses except sodium balance,
as his data were similar to the HBP group as a whole. The
clinical characteristics of the two groups are displayed in Table
1. The sex distribution and age (NBP 25, 29, 30, 34, 37, 39, 42
years vs. HBP 32, 32, 33, 34, 35, 41, 44, 46, 48 yrs) were not
significantly different between the two groups. As per selection
of patients, the baseline MAP was significantly higher in the
hypertensive (HBP) group compared to the normotensive
(NBP) group, (114.9 1.2 vs. 89.3 0.9 mm Hg, P C 0.0001).
All admission blood counts and chemistries were within normal
limits in both groups of patients.
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Table 1. Clinica1 characteristics of study groups
Baseline
Number Number Age MAPN male female yrs mm Hg
HBP 9 4 5 38.6 2.2 114.9 1.2
NBP 7 2 5 33.9 2.3 89.3 0.9
P value NS NS <0.0001
Abbreviations are: HBP, hypertensive patients; NBP, normotensive
patients; MAP, mean arterial pressure.
The clearance results are shown in Table 2. Creatinine
clearances and inulin clearances were similar in the two groups.
Although PAH clearances and filtration fractions (inulin
clearance/PAH clearance) were not significantly different be-
tween the HBP and NBP patients, the PAH clearance tended to
be lower and the filtration fraction higher in the hypertensive
subjects. The renal vascular resistance was 12,902 1,075
dyne sec . cm5 in the HBP group and 9,974 2,031
dyne . sec . cm5 in the NBP group (P = 0.0589).
Sodium balance
Cumulative sodium (Na) balance at the end of the low sodium
diet was significantly different between the two groups, with the
HBP group having a negative balance of 251 47 mEq Na and
the NBP group having a negative balance of 107 24 mEq Na,
P < 0.03 (Table 3). Moreover, the 24-hour urine sodium on the
first day of the study was significantly higher in the HBP
patients compared to the NBP patients (115 14 vs. 62 8
mEq Na, P < 0.002). The positive sodium balance during the
period of the high sodium diet was not statistically different
between the two groups (480 112 HBP vs. 409 35 NBP mEq
Na, NS). The cumulative sodium balance for the entire study
period (from the beginning of the low sodium diet to the end of
the high sodium diet) was also similar (229 137 HBP vs. 302
37 NBP mEq Na, NS). When cumulative sodium balance was
normalized for subjects' body weight, there was no difference
between the HBP and NBP group at the end of either the low
sodium or high sodium diet period. Although both groups lost
weight on the low sodium diet, the hypertensive patients lost
significantly more weight than the normotensive patients (2.5
0.5 vs. 0.7 0.3 kg, P < 0.005). During the high sodium diet,
the weight gain was similar in the two groups (1.1 0.6 HBP vs.
0.6 0.3 NBP kg, NS). There was no indication that the
hypertension was salt sensitive, in that the blood pressures did
not change significantly in response to salt loading in either
group.
Plasma volumes
Plasma volumes (PV) on the low sodium diet were not
significantly different between the HBP and NBP subjects (29.3
1.8 ml/kg HBP and 35.7 4.2 ml/kg NBP, NS). In response
to the high sodium diet, PV increased significantly in both
groups (29.3 to 36.0 mI/kg HBP, P < 0.03; 35.7 to 45.0 mI/kg
NBP, P < 0.04); these increments were not significantly dif-
ferent between the two groups. Analyzing plasma volumes
normalized for body surface area did not alter the results.
Table 2. Clearance results
Cr C1fl
CPAH
Filtration
fraction
%mI/mm
HPB 127 7 101 10 387 30 24 3
NBP 114 12 91 10 505 54 18 1
P value NS NS NS NS
Abbreviations are: C, creatinine clearance; C, inulin clearance;
CPAH, PAH clearance.
Cumulative
Low Na High Na balance
HBP —251 47 480 112 229 147
NBP —107 24 409 35 302 37
P value <0.03 NS NS
Renin-angiotensin-aldosterone system
Values were similar in the HBP and NBP subjects at all time
points of measurement (Table 4). Plasma aldosterone levels
were not significantly different between the HBP and NBP
patients, and were stimulated by a low sodium diet and upright
posture (Table 5).
To functionally assess the contribution of the renin-angioten-
sin system to hypertension, the angiotensin converting enzyme
inhibitor, captopril, was administered. Supine PRA was ob-
tained one hour after administration of 25 mg captopnl and
compared to the baseline two-hour supine PRA. On the high
sodium diet the percent fall in MAP and the dose of captopril
administered were not significantly different between the NBP
and HBP patients. The fall in MAP was similar in the NBP and
HBP groups on both the low and high sodium diets. On the low
sodium diet PRA increased from 5.1 0.9 to 11.3 2.3
mg/mi/hr (P < 0.02) in the HBP patients and from 7.5 1.6 to
13.3 2.6 mg/mi/hr (NS) in the NBP patients. Plasma renin
activity was suppressed on the high sodium diet yet did rise
significantly with angiotensin II blockade, 1.6 0.4 to 6.0 2.3
mg/mi/hr (P < 0.02) in HBP patients but not in NBP patients
(1.7 0.7 to 2.4 0.9 mg/ml/hr, NS). Thus the increase in renin
during Captopnl was significantly greater in HBP as compared
to the NBP group (P < 0.04) on a high sodium diet.
A trial natriuretic factor
Atrial natriuretic factor was measured on admission and was
similar in the two groups (43.1 6.7 HBP vs. 40.7 9.1 NBP
pg/mI, NS). On the low sodium diet there was no significant
difference in the supine and upright ANF values between the
HBP and NBP patients (Fig. 1). On the high sodium diet in the
supine position ANF levels increased significantly in both
groups (34.0 to 83.7 pg/mI HBP, P < 0.01; 26.6 to 57.1 pg/mI
NBP, P < 0.03); however, the increment in ANF was signifi-
cantly higher in the HBP patients compared to the NBP patients
(+49.7 6.4 HBP vs. +30.5 10.0 pg/ml NBP, P < 0.05).
Furthermore, exercise resulted in higher ANF values in the
HBP than the NBP patients on both the low sodium (60.5 vs.
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Table 4. Plasma renin activity (PRA), ng/ml/hr
Admission
Supine
Low Na Low Na
Upright
Low Na
Exercise
High Na
Supine
.
High Na
Upright
.
High Na
Exercise
HPB
NBP
P value
3.1 0.6
2.9 0.6
NS
5.1
7.5
0.9
1.6
NS
9.0 l.oa
9.4 1.5
NS
5,4 1.0
7.8 1.5
NS
1.6 0.3'
1.7 07b
NS
2.3 04b
3,4 l.2'
NS
2.2 0.4
2.7 0.8
NS
a The HBP demonstrated a significant increase in plasma renin with upright versus supine posture on the low sodium diet and the NBP
demonstrated a similar phenomenon on the high sodium diet, P < 0.05.b Both HBP and NBP demonstrated a significant suppression of PRA on the high versus low sodium intake in both the supine and upright
positions, P < 0.05.
Table 5. Plasma aldosterone, pg/mI
Admission Low Na
Low Na
Upright
Low Na
Exercise
High Na
Supine
High Na
Upright
High Na
ExerciseSupine
HBP
NBP
P value
11.2 1.1
13.6 2.8
NS
22.4 3.9
31,7 7.6
NS
61.0 7,3a
58.7 4,9a
NS
35.4 2.3
42.9 7.7
NS
7.0 0.9k'
NS
12.7 25a,b
16.8 5•5aI
NS
11.2 2.3
12.4 3.0
NS
a Both the HBP and NBP groups demonstrated a significant increase in aldosterone from supine to upright position on the low and high sodium
diets, P < 0.05.
b Both HBP and NBP groups demonstratçd a significant depression of aldosterone from the low to high sodium diet in both the supine and
upright positions, P < 0.05.
Fig. 1. Atrial natriuretic factor (ANF) on low
and high sodium diets during supine position
(Su), upright position (Up) and exercise (Ex)
in normotensive (clear bar) and hypertensive
(solid bar) groups. ANF concentrations were
significantly higher in exercise in HBP
compared to NBP group on both diets. ANF
concentrations increased significantly from
low to high sodium diet in both groups in both
positions. The increase was greater in the
HBP group than the NBP group for the supine
position (P = 0.05).
33.3 pg/mI, P < 0.002) and high sodium diets
pg/mi, P = 0.05).
Hemodynamics
(106.6 vs. 59.4
In response to exercise, mean arterial pressure increased
significantly in each group on both the low and high salt diets
(Fig. 2). This was accompanied by significant rises in cardiac
index and falls in total peripheral resistance in both groups (Fig.
2). However, there was a greater increment in cardiac index in
the HBP patients compared to the NBP patients on the low
sodium (3.9 0.5 vs. 2.5 0.4 liter/mm/rn2, P < 0.04) and high
sodium diets in response to exercise (4.0 0.6 vs. 2.1 0.3
liter/min/m2, P < 0.05; Fig. 3).
Sympathetic nervous system
Plasma norepinephrine concentrations were drawn from
indwelling catheters on admission in the supine position, and on
the low and high sodium diets after two hours supine, two hours
upright, and exercise on the treadmill. As can be seen in Table
6, none of the levels obtained were significantly different
between the two groups. Although supine plasma NE levels
were relatively insensitive to dietary manipulation of sodium
intake, upright plasma NE was suppressed on the high as
compared to the low sodium intake on both HBP and NBP
groups (618 44 vs. 467 49 pg/mI HBP, P < 0.01; and 673
70 vs. 454 17 pg/ml NBP, P < 0.04). Plasma NE levels
increased significantly as expected with upright posture in both
groups of subjects on both the low and high sodium diets, The
response to the clonidine suppression test was indistinguishable
in the two groups of patients. Both the NBP and HBP subjects
displayed similar falls in MAP (16 percent in NBP and 14
percent in HBP, NS). There were no significant correlations in
either the HBP or NBP subjects between the resting plasma NE
level and the decrease in MAP, nor the decrement in MAP and
the decrement in plasma NE after clonidine.
Alpha adrenergic blockade utilizing phentolamine intrave-
Low sodium
150 1
10j P<0.00211U—z I
50 F
TlT.uI
Su Up Ex
P 0.05
[1
High sodium
LI r Ex
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Urinary prostaglandin
2000 20 r
1000
P = 0.02[1
—10001-
:1
A Low sodium
Total peripheral
resistance,
dyne- Sec• cm5
MAP,
mm Hg
Cl,
liter/minim2
X TPR,
dyne - Sec - cm
2000
1000
0
A Low sodium
Mean arterial
pressure,
mm Hg
120
B High sodium
120
- -,
100
80
Cardiac index,
liter/minim2
2:
8.0
6.0
4.0
2.0
0.0
8.0
6.0
4.0
2.0
0.0
B High sodium
it'
—2000 r
P = 0.04
0Rest Exercise Rest Exercise Rest Exercise 0
Fig. 2. MAP, cardiac index and total peripheral resistance on low and
high sodium diets during rest and exercise in both NBP (dotted line)
and HBP (solid line) group. * represents significant difference from rest
to exercise, P < 0.05.
Fig. 3. The hemodynamic changes from rest to exercise. There was no
significant difference in the increase in MAP between NBP (clear bar)
and HBP (hatched bar) on either diet. Cardiac index increased signifi-
cantly more in HBP compared to NBP group. Total peripheral resis-
tance fell significantly more in HBP group than NBP group on high
sodium diet.
nously was also performed. The infusion was to be stopped if a distortion of intrarenal vasculature. The present comprehensive
fall in MAP of ten percent occurred, the heart rate increased 15 study was therefore performed to investigate the hemodynamic-
beats per minute, or a total of 30 milligrams of phentolamine volume and neurohumoral factors which could be related to
had been administered. However, there was no significant these possible pathogenetic mechanisms of ADPKD hyperten-
decrease in MAP in either group on the low or high sodium diet sion.
after a total of 30 milligrams of phentolamine. In regards to altered sodium handling and plasma volume
D'Angelo et a! reported that nonazotemic ADPKD subjects
were unable to excrete an acute sodium load [27], and Nash
Urinary PGE2 excretions are displayed in Table 7. There was noted that six of seven nonazotemic PKD patients became
no significant difference between the HBP and NBP subjects. normotensive on a low sodium (10 mEq/day) diet [14]. Howev-
The ratio of urinary PGE2 to PRA was also examined in both er, in the present study plasma volume was not different
groups (Table 7); these ratios were also not significantly dif- between the NBP and HBP groups while they were ingesting
ferent between groups on both the low and high sodium diets. either a high or low sodium diet. In addition, the HBP group did
Discussion
not retain more sodium on a high sodium diet. Moreover,
neither a low nor high sodium diet intake for five days was
ADPKD is a disorder characterized by remarkable cyst found to modulate blood pressure in the hypertensive ADPKD
development within the kidney. This cystic deformation is patients. Thus, the present study does not support a strict
accompanied by hypertension in approximately sixty percent of volume-mediated mechanism for the hypertension in ADPKD.
individuals prior to the onset of azotemia [10]. In fact, ADPKD The high sodium diet was found to be associated with a
individuals with hypertension manifest more severe cystic significantly greater increase in atrial natriuretic factor (ANF) in
involvement as assessed by larger kidneys and more cysts than the hypertensive ADPKD patients. ANF secretion is thought to
do normotensive ADPKD individuals [26]. Thus, it is logical to result primarily from an increase in atrial stretch or wall tension
attempt to relate the consequences of cyst involvement to the [24, 28—31] which could occur from an increased plasma volume
potential mechanism of hypertension in ADPKD patients. Such or increase venoconstriction and cardiac pre-load. Plasma
a relationship could be via altered sodium excretion secondary volume expansion during increased dietary sodium intake
to tubular abnormalities or via intrarenal ischemia secondary to would increase cardiac filling pressures and would be expected
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Table 6. Plasma norepinephrine values, pg/mI
Admission Low Na Low Na
Upright
Low Na
Exercise
.
High Na
Supine
.
High Na
Upright
.High Na
ExerciseSupine
HBP
NBP
Pvalue
254 44
253 39
NS
299 50
321 32
NS
618 44
673 7O
NS
956 228
768 106
NS
287 43
226 47
NS
467 49a.b
454
NS
1002 100
958 125
NS
a In both HBP and NBP groups there was a significant increase in NE levels from supine to upright position on both low and high sodium diets, P
<0.05.b Inboth the HBP and NEP groups there was a significant decrease in plasma NE levels from a low to high sodium diet in the upright position, P
<0.05.
High Na
POE2!
POE2 PRA
ng/24 hr ratio
239±49 195±65
324±64 425±141
NS NS
Table 7. Urinary prostaglandin results
Low Na
POE2
ng/24 hr
HBP 258 112
NBP 213 42
P NS
POE2!
PRA
ratio
66 25
39 11
NS
Abbreviations are: POE2, prostaglandin E2; PRA, plasma renin
activity.
to be associated with an increase in ANF secretion. However,
since plasma volumes increased by a similar degree in the HBP
and NBP patients, it was anticipated that ANF would rise
comparably in the two groups. Thus, the observed greater
increase in plasma ANF levels during a high sodium diet in the
HBP patients suggested greater venoconstriction as compared
to NBP patients. Plasma atrial natriuretic factor was also found
to increase during exercise to a significantly higher concentra-
tion in the HBP patients as compared to NBP patients on both
the low and high sodium intake. In conjunction with this effect,
cardiac index increased significantly more during exercise in the
HBP patients compared to NBP patients in both the low and
high salt diets. These findings suggested that an increase in
cardiac pre-load during a high sodium intake and exercise may
occur secondary to venoconstriction in the hypertensive
ADPKD patient. Such an effect could account for both the
significantly higher plasma atrial natriuretic factor and the
significantly greater increase in cardiac index observed during
exercise in the hypertensive as compared to the normotensive
patients with ADPKD.
It is known that the sympathetic nervous and renin-angioten-
sin systems may be factors in venoconstriction and thereby
enhance cardiac pre-load. In this regard, however, no differ-
ences between the hypertensive versus the normotensive
ADPKD patients were found in plasma norepinephrine concen-
tration during either basal circumstances or with changes in
posture and sodium intake. Moreover, differences in sympa-
thetic sensitivity seemed unlikely, since neither the administration
of the central alpha-2-agonist, clonidine, nor the alpha-adrener-
gic blocker, phentolamine, differentiated the hypertensive as
compared to the normotensive ADPKD patients.
It is therefore logical to suggest the renin-angiotensin system
as the link between the observed relationship of renal structural
alterations and the hypertension in ADPKD [26]. Specifically,
ADPKD has been shown to be associated with thinning and
ADPKD Subject
ii
Increased cyst number/s/ Increased local renin// Increased angiotensin/
Increased renal Increased
vascular resistance venoconstriction
Increased ANF Increased preload
Increased
cardiac output
increased I
sodium excretion
Increased
blood pressure
Fig. 4. A proposed pathogenetic scheme for hypertension in ADPKD.
tortuosity of renal vasculature secondary to renal cyst enlarge-
ment [32, 33], a circumstance which might be expected to cause
local ischemia and renin stimulation. However, previous stud-
ies have failed to demonstrate an increase in plasma renin
activity (PRA) in hypertensive patients with ADPKD [11, 12,
14]. Moreover, Anderson et al showed that there was no
hypotensive response to an angiotensin II inhibitor, saralasin,
in the ADPKD subjects, in contrast to a marked decrease in
blood pressure which occurred in patients with renal artery
stenosis [11]. However, an agonist effect of saralasin cannot be
excluded in this study and therefore could have obscured a role
of the renin-angiotensin system in the ADPKD hypertension.
It has been suggested that the administration of converting
enzyme inhibitors, such as captopril, might be a more sensitive
means to incriminate the renin-angiotensin system in hyperten-
sive states [34]. In the present study, the use of captopril did
not differentiate between the hypertensive and normotensive
ADPKD patients as assessed by changes in blood pressure.
Interestingly, however, on both a low and high sodium intake
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the rise in PRA during captopril administration was significantly
greater in the hypertensive ADPKD patients compared to
normotensive patients. In this regard, it is known that blockade
of angiotensin removes the hormone's inhibitory effect on renin
release, therefore, PRA increases. In fact, some authors have
suggested that a rise in PRA may be more sensitive than a fall
in blood pressure as an index of angiotensin blockade, either by
angiotensin antagonism or inhibition of converting enzyme [34,
35]. It is also important to emphasize that the rise in PRA during
converting enzyme inhibition in the hypertensive ADPKD
occurred during the high sodium intake, a circumstance of
increased angiotensin vascular sensitivity [36].
Taken together, the present results are compatible with the
following hypothesis (Fig. 4). The renal cyst involvement ini-
tiates events in ADPKD patients which lead to hypertension. In
this regard, prior to renal deterioration ADPKD patients with
hypertension have significantly more renal cystic involvement
than normotensive ADPKD patients [26]. This cystic involve-
ment could lead to local ischemia and increased generation of
renin-angiotensin. This proposed link is supported by the sig-
nificantly greater rise in PRA in response to converting enzyme
inhibition in the HBP compared to NBP subjects.
The other results support venoconstriction in the HBP com-
pared to the NBP subjects, an effect which could be angioten-
sin-mediated. A major difference between normotensive and
hypertensive ADPKD patients was the elevated plasma ANF
concentrations during a high sodium intake or exercise on a
high or low diet. These plasma ANF elevations occurred in the
hypertensive ADPKD patients in the absence of differences in
plasma volume between the NBP and HBP patients with
ADPKD. In the absence of differences in volume expansion to
explain the higher plasma ANF and cardiac indices in the
hypertensive ADPKD patients, it is reasonable to propose
greater venoconstriction causing enhanced cardiac pre-load in
the hypertensive as compared to the normotensive ADPKD
patients. The elevation in cardiac index, as most clearly shown
during exercise, would, however, not be expected to sustain
hypertension unless accompanied by impaired renal response,
thus necessitating a higher renal perfusion pressure to maintain
sodium balance. While clearly not definitive, and therefore
requiring further studies, the present results do allow for this
potential hypothesis of the pathogenesis of hypertension in
ADPKD patients with normal renal function.
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